N-heteroaryl substituted aniline derivatives as HCV-antivirals

Patent metadata

Field	Value
Publication number	US-9382218-B2
Application number	US-201414768881-A
Country	US
Kind code	B2
Filing date	Feb 27, 2014
Priority date	Mar 5, 2013
Publication date	Jul 5, 2016
Grant date	Jul 5, 2016

Abstract

The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

First claim

The invention claimed is:

1. A compound
wherein said compound is
N 5 -(3,5-Dichloro-phenyl)-1H-pyrazole-3,5-diamine;
N 5 -(3,5-Dichloro-4-fluoro-phenyl)-1H-pyrazole-3,5-diamine;
(3,5-Dichloro-phenyl)-(5-methyl-[1,3,4]oxadiazol-2-yl)-amine;
N 3 -(3-Trifluoromethyl-phenyl)-[1,2,4]oxadiazole-3,5-diamine;
N 5 -(3,5-Dichloro-phenyl)-[1,2,4]oxadiazole-3,5-diamine;
N 3 -(3,5-Dichloro-phenyl)-[1,2,4]oxadiazole-3,5-diamine;
N 5 -(3-Chloro-5-trifluoromethyl-phenyl)-[1,2,4]oxadiazole -3,5-diamine;
N 3 -(3-Chloro-5-trifluoromethyl-phenyl)-[1,2,4]oxadiazole-3,5-diamine;
N-[4′-(3-Amino-[1,2,4]oxadiazol-5-ylamino)-6′-chloro-2′-trifluoromethyl-biphenyl-3-yl]-methanesulfonamide;
N-[4′-(5-Amino-[1,2,4]oxadiazol-3-ylamino)-6′-chloro-2′-trifluoromethyl-biphenyl-3-yl]-methanesulfonamide; or
N 2 -(3,5-Dichloro-phenyl)-oxazole-2,5-diamine, or a pharmaceutically acceptable salt thereof.

2. A method for treating a Hepatitis C Virus (HCV) infection, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

4. The method of claim 2 , further comprising the step of administering a combination of antiviral agents that inhibits replication of HCV.

5. The method of claim 2 , further comprising the step of administering an immune system modulator or an antiviral agent that inhibits replication of HCV, or a combination thereof.

6. The method of claim 5 , wherein the immune system modulator is an interferon or a chemically derivatized interferon.

7. The method of claim 5 , wherein the antiviral agent is selected from the group consisting of a HCV protease inhibitor, a HCV polymerase inhibitor, a HCV helicase inhibitor, a HCV NS5A inhibitor, or any combination thereof.

Assignees

• Hoffmann La Roche

Inventors

• Plancher Jean-Marc
• Weikert Robert James

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• C07D271/07 Primary

  with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical · CPC title